北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学公共卫生学院  > 期刊论文
学科主题: 公共卫生
题名:
Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study
作者: Yang, Li1; Christensen, Torsten2; Sun, Fengyu3; Chang, Jinghua3
关键词: Chinese setting ; cost-effectiveness ; cost-utility ; insulin detemir
刊名: VALUE IN HEALTH
发表日期: 2012
DOI: 10.1016/j.jval.2011.11.018
卷: suppl.S, 期:1, 页:S56-S59
收录类别: SCI ; SSCI
文章类型: Article
WOS标题词: Social Sciences ; Science & Technology
类目[WOS]: Economics ; Health Care Sciences & Services ; Health Policy & Services
研究领域[WOS]: Business & Economics ; Health Care Sciences & Services
关键词[WOS]: THERAPY CONVERSION ; MELLITUS ; OUTCOMES ; ASPART
英文摘要:

Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) to insulin detemir (IDet) in patients with type 2 diabetes in the setting of Chinese secondary and tertiary hospitals. Methods: A published and validated computer simulation model of diabetes (the Center for Outcomes Research model) was used to make the long-term (30 years) projection of health economic outcomes. Patient demographic information and clinical end points were derived from a subgroup analysis of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation (PREDICTIVE) study. Baseline risk factors and racial characteristic data were obtained from Chinese cohort studies. The diabetes management and complications costs were obtained from Chinese published data and adjusted to 2010 values by using the Chinese consumer price index. An annual discounting rate of 3% was used for both health and cost outcomes, and one-way sensitivities analysis was performed, which illustrated that the results were robust. Results: Conversion to IDet from IGla was projected to improve patient life expectancy by 0.06 year and 0.48 quality-adjusted life-years. Drug costs and management costs of diabetes mellitus were increased by US$368 (US$17,466 vs. US$17,097) and US$31 (US$5464 vs. US$5433), respectively. However, the costs of complications, including cerebrovascular disease, renal complications, ulcer/amputation/neuropathy, eye complications, and hypoglycemia events, were reduced by US$ 819 (US$21,294 vs. US$22,114), resulting in a total direct medical cost saving of US$420 when converting to IDet. Conclusions: Conversion to IDet from an IGla regimen improved life expectancy and was a cost-saving treatment approach in a Chinese setting.

语种: 英语
WOS记录号: WOS:000299317000010
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/61629
Appears in Collections:北京大学公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Novo Nordisk AS, Virum, Denmark
2.Novo Nordisk China Pharmaceut Co Ltd, Beijing, Peoples R China
3.Peking Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Beijing 100191, Peoples R China

Recommended Citation:
Yang, Li,Christensen, Torsten,Sun, Fengyu,et al. Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study[J]. VALUE IN HEALTH,2012,suppl.S(1):S56-S59.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yang, Li]'s Articles
[Christensen, Torsten]'s Articles
[Sun, Fengyu]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yang, Li]‘s Articles
[Christensen, Torsten]‘s Articles
[Sun, Fengyu]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace